CohBar is an innovative biotechnology company whose mission is to treat age-related diseases and extend healthy life span through the discovery of novel mitochondrial-derived peptides (“MDPs”) and the advancement of their development into clinically relevant and commercially successful therapeutics. Company founders Dr. Pinchas Cohen (Dean of the Davis School of Gerontology at USC) and Dr. Nir Barzilai (Director of the Institute for Aging Research at Albert Einstein College of Medicine), whose research has been supported by more than $30M in government grants, have discovered a pipeline of MDP’s that have the potential to slow the progress of and protect against a wide range of major age-related diseases including diabetes, Alzheimer’s disease, cardiovascular disease and cancer. As a result, CohBar’s research and development platform is uniquely positioned to address the enormous health needs of our rapidly growing aging population with a novel family of naturally occurring (non-synthetic) MDP-based therapeutics.
More than 10 years ago, Dr. Cohen and Dr. Barzilai, leaders in the field of the biology of aging, made the seminal discovery that an MDP (Humanin) communicates with organs regulating energy metabolism and glucose homeostasis. Since then, more than a dozen mitochondrial-derived peptides have been identified. This scientific breakthrough, for which patents have been granted and exclusively licensed by the company, forms the basis for CohBar’s early drug development targeting a variety of therapeutic indications. The groundbreaking findings of the existence of multiple MDPs have garnered numerous prestigious awards for the CohBar founders from the NIH (including the NIA EUREKA award, NIH Director and Merit Awards).
CohBar has attracted a superior group of scientists and biotechnology veterans who help shape the Company’s development. CohBar ’s founders include David Sinclair, PhD, professor of genetics at Harvard Medical School and John Amatruda, MD, former Senior Vice President, Diabetes and Obesity, at Merck Research Laboratories. In addition, CohBar’s has a hands-on, experienced and prestigious Scientific Advisory Board (SAB), comprised of Amir Lerman, MD. Professor of Medicine, Mayo Clinic, Domenico Accili, MD, Professor of Medicine, Columbia University College of Physicians & Surgeons, Ronald Khan, MD, Professor of Medicine at Harvard Medical School, James Livingston, PhD, Vice President of Biology at NovaTarg Therapeutics and formerly with Glaxo Smith Kline. Their experience as scientists, medical doctors and senior executives at startup biotechnology and major pharmaceutical companies provides valuable assistance in guiding CohBar’s strategic decisions.
As many large pharmaceutical companies look to specialized discovery and development biotechnology companies for licensing and acquisition of new therapeutics, CohBar’s leading MDP platform and pipeline potentially enable a variety of significant development and commercialization partnerships in multiple pharma market sectors such as diabetes and Alzheimer’s, each with annual sales in the billions of dollars.
CohBar’s corporate culture mixes scientific excellence with a dynamic fast-paced engaging environment. Most importantly, the Company aims to create efficacious therapeutics that benefit patients with major diseases while building a profitable enterprise that attracts and rewards its shareholders, founders and employees.
CohBar’s mission is to use cutting edge science to provide new treatments to help society address the alarming growth of the diabetes epidemic. According to estimates by the CDC, there are approximately 105 million people have diabetes or prediabetes in the U.S. Nearly 26 million Americans have diabetes, a 10% increase from 2008, and an estimated 79 million adults have prediabetes, a 39% increase from 2008. Diabetes is the seventh-leading cause of death in the U.S. and is a major cause of heart disease, stroke and high blood pressure. Diabetes costs the US $174 billion annually. If current trends continue, as many as 1 in 3 adults in the US could have diabetes by 2050. CohBar is focused on a newly discovered peptide called Humanin, which could have demonstrable therapeutic value in type 2 diabetes. In laboratory testing, Humanin has several potent anti-diabetic effects that if validated in clinical trials, could represent a major advancement in the treatment of diabetes.
All countries are experiencing a growth in the number of elderly people in the population. By 2020 the world population of elderly people is expected to have tripled, with an estimated 700 million people aged 65 years or older. Diseases of aging, including neurodegeneration, metabolic syndrome, and various malignancies, affect the majority of the elderly and require a better understanding of the biological processes involved. Recent studies indicate that growth factors are central to various aging related processes affecting cell survival and senescence have been proposed as possible approaches to the aging problem. CohBar is developing a family of novel growth and survival factors called MDPs, which appear to decline with age and may represent important therapeutic and diagnostic targets for a number of diseases. In addition, these MDPs have been linked to long life span in humans and are being developed as new treatments. For more information on aging and longevity, please visit http://www.einstein.yu.edu/centers/aging/.